The Swiss pharmaceutical company, Novartis, announced that its drug, Kisgali, to reduce the risk of recurrence of breast cancer in women who were diagnosed with it at an early stage, achieved great success and effectiveness in an important clinical trial. The company said that a number of independent consultants advised it to stop the experiment, because the interim analysis of the aforementioned drug showed a clear benefit for those who volunteered for the clinical trial. The experiment indicated the effectiveness of Kisgali if it was given to the patient along with the traditional oncology treatment she was receiving. Novartis stated that the Mesgali drug was approved for the treatment of women with breast cancer as a result of factors related to hormones, and in the event that the cancer spreads to the rest of the body. And competing with Kisgali in the market is the drug Ibrance, which was invented by the American pharmaceutical company, Pfizer.
The market value of the pharmaceutical company 89Bio jumped to about $ 1 billion, after it announced promising data for a clinical trial it conducted on the drug Pegosavirmin, which its scientists developed to treat steatohepatitis, which is not caused by alcohol abuse. Pharmaceutical companies have been trying for years to create an effective drug for cirrhosis of the liver, without much success. It is a multi-billion dollar market. The aforementioned company must still conduct advanced stages of the clinical trial to provide data confirming the effectiveness of its new drug.
Okaz (Jeddah) @Okaz_online